2022 issue 1

Back

Volume 38, issue 1

Review article

Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski1, Jerzy Samochowiec1
1. Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland; Katedra i Klinika Psychiatrii, Pomorski Uniwersytet Medyczny, Szczecin, Polska
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 35–47
Date of publication: 28-07-2022
DOI: https://doi.org/10.5114/fpn.2022.117700
Keywords: psychotropic drugs, nomenclature, neuroscience

Abstract

Objectives. The aim of the study was to present the general rules and limitations of the proposed new system of classification of pharmacological substances used in psychiatry, i.e. Neuroscience-based Nomenclature (NbN).

Review of selected literature. Current literature on NbN and its possibilities in the classification of medicinal substances was reviewed. The currently used Anatomical Therapeutic Chemical (ATC) Classification and its limitations are presented. The structure of NbN is discussed and its practical use is described. The limitations of the NbN classification were also analysed.

Conclusions. Based on the current literature, we can conclude that the NbN classification of psychopharmaceuticals may turn out to be a breakthrough in this field. Due to its features, it is a system that is regularly updated. Thanks to the vast amount of information and the available mobile application, the NbN classification has a chance to enter everyday clinical practice.

Address for correspondence:
Piotr Podwalski
Katedra i Klinika Psychiatrii
Pomorski Uniwersytet Medyczny
26 Broniewskiego Str., 71–460 Szczecin, Poland
email: piotr.podwalski@pum.edu.pl